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Abstract
Home mechanical ventilation (HMV) is an effective long-
term treatment for chronic hypercapnic respiratory failure. 
In addition to the established practice of providing HMV for 
the treatment of chronic ventilatory failure in slowly pro-
gressive neuromuscular and chest wall disease, there is ac-
cumulating evidence for improvement of quality of life and 
prolongation of survival by HMV in highly prevalent diseases 
like chronic obstructive pulmonary disease and ever-in-
creasing obesity hypoventilation syndrome as well as rap-
idly progressive neuromuscular disease. The key concepts 
for successful HMV are an experienced team selecting the 
right patients, timely initiation of adequate ventilation via an 
appropriate interface, and monitoring effectiveness during 
regular long-term follow-up. Coaching of patients with 
chronic respiratory failure on long-term HMV within a dedi-
cated service and collaborations with community services 
for home care are essential. The current review describes var-
ious important practical aspects of HMV that remain fron-
tiers in the implementation of the current knowledge in clin-
ical practice and may help in providing effective HMV to all 
those in need. © 2019 S. Karger AG, Basel
Introduction
Home mechanical ventilation (HMV) is an effective 
long-term treatment that improves quality of life and sur-
vival in patients with chronic hypercapnic respiratory fail-
ure due to different underlying conditions such as neuro-
muscular and chest wall disease (NMD/CWD), obesity-
related ventilatory failure, and obstructive airway disease 
[1–3]. The hallmarks of chronic type II respiratory failure 
(ventilatory failure, failure of the respiratory muscle pump) 
are chronic hypercapnia (arterial partial pressure of CO2 
[paCO2] > 6 kPa) and compensated respiratory acidosis by 
retention of bicarbonate. Typical findings in addition to 
the arterial blood gas constellation of chronic respiratory 
failure during wakefulness are a sleep-associated increase 
of alveolar hypoventilation, frequent respiratory tract in-
fections, and signs of cor pulmonale and polycythemia.
The most important groups of patients with chronic 
respiratory failure successfully treated with HMV are pa-
tients with obesity hypoventilation syndrome (OHS), pa-
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tients with NMD (e.g., muscular dystrophy or motor neu-
rone disease) or CWD (e.g., kyphoscoliosis), and patients 
with chronic obstructive pulmonary disease (COPD). 
However, the cause of alveolar hypoventilation can be 
found anywhere on the neuromuscular axis from the re-
spiratory centre down to the respiratory muscles, the 
lungs, or the chest wall.
Positive pressure ventilation is nowadays the standard 
treatment for chronic respiratory failure. HMV with pos-
itive pressure ventilation is either applied non-invasively 
via a mask or invasively through a tracheostomy. The 
main goals of mechanical ventilation in chronic respira-
tory failure are to improve quality of life and to prolong 
survival. This is achieved by allowing the ventilator to as-
sist the failing respiratory pump in order to provide ad-
equate ventilation and to reduce the work of breathing by 
unloading the respiratory muscles and improving pulmo-
nary mechanics. To assure effectiveness, optimise patient 
comfort and patient-ventilator synchrony, and avoid ad-
verse effects, titration and monitoring of mechanical ven-
tilation as well as patient education are essential. A regu-
lar follow-up is needed to adapt the ventilator according 
to the clinical course of the patient’s disease and to recog-
nise potential complications. In addition, many underly-
ing conditions that cause chronic respiratory failure are 
also associated with manifestations in other organ sys-
tems or common comorbidities that have to be recog-
nised by physicians treating patients with chronic respi-
ratory failure. Notably, the provision of care and imple-
mentation standards for non-invasive ventilation (NIV) 
services may differ across health care systems and coun-
tries. This review outlines practical considerations for 
HMV in chronic respiratory failure.
Phases of Mechanical Ventilation from Initiation to 
Long-Term Care
Each phase of long-term mechanical ventilation from 
initiation of NIV or tracheostomy ventilation over dis-
charge from the hospital into the community to provision 
of long-term follow-up for HMV is associated with spe-
cific challenges. Monitoring of effectiveness of HMV is 
mandatory in all phases.
The indication to start HMV either arises during regu-
lar follow-up in diseases with progressive respiratory 
muscle weakness (e.g., in NMD) as a consequence of 
symptoms suggesting respiratory failure in combination 
with arterial blood gas analysis or a sleep study (with 
transcutaneous pCO2 measurement), or during symp-
tomatic acute on chronic respiratory failure as is often the 
case in COPD and OHS. In COPD, persisting chronic 
respiratory failure should be demonstrated after an acute 
exacerbation before initiating long-term HMV [2]. Prog-
nosis of patients with persisting hypercapnic respiratory 
failure after an acute exacerbation is poor compared to 
patients with transient hypercapnia or eucapnia [4, 5]. 
Recent landmark trials in COPD have shown that patient 
selection for HMV after initiation of NIV during an acute 
exacerbation of COPD should include a follow-up assess-
ment with arterial blood gas analysis 2–4 weeks after the 
exacerbation demonstrating persisting hypercapnic re-
spiratory failure [2, 6].
In conditions with expected chronic respiratory failure 
within the course of disease, HMV should be discussed 
timely and the patient educated prior to initiation. Initia-
tion of NIV in stable chronic respiratory failure should 
include titration during physiological monitoring by a 
specialised team. Adaptation can be performed on the 
ward or sleep laboratory using respiratory polygraphy or 
in the high-dependency unit depending on patient needs. 
The goal is to achieve patient comfort and NIV effective-
ness as assessed by correction or reduction of hypercap-
nia. Elective initiation of NIV usually requires a short in-
hospital stay; however, it might be achieved in an outpa-
tient setting in a subgroup of patients [7, 8]. It has been 
shown that there is no difference in effectiveness of NIV 
or ventilator usage when NIV is initiated in the outpatient 
setting in carefully selected, stable patients with NMD/
CWD without cognitive impairment or bulbar weakness 
compared to in-hospital initiation of NIV [7, 8]. Out-pa-
tient initiation of NIV in stable patients with chronic hy-
percapnic respiratory failure and other underlying dis-
ease is reality in some centres. However, there is a lack of 
conclusive trials comparing inpatient and outpatient set-
up of HMV. Monitoring serves to demonstrate correction 
of respiratory failure, to optimise patient-ventilator syn-
chrony, and to avoid overtreatment and adverse effects 
such as haemodynamic compromise. It also helps to de-
cide whether different day-time and night-time settings 
might be needed in 24-h HMV. When proven tolerable 
and effective, an initially close follow-up is recommend-
ed, followed by expansion of the intermediate intervals 
according to the tempo of disease progression and com-
plicating factors. HMV via tracheostomy commonly fol-
lows endotracheal invasive mechanical ventilation in the 
intensive care unit due to acute on chronic respiratory 
failure and subsequent weaning failure. In an intensive 
care unit setting, blood gas monitoring by an indwelling 
arterial catheter is usually given. However, tracheostomy 
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is sometimes performed electively, e.g., when NIV is no 
longer applicable due to inadequate bulbar muscle func-
tion or when 24-h ventilator support is needed. Titration, 
monitoring, training (swallowing, speech, de-cuffing, 
suctioning, etc.) is then usually performed in a high-de-
pendency unit by an interdisciplinary team. Tracheosto-
my ventilation implicates organising care that guarantees 
patient security (e.g., special-care home or intensive 
training of family members). Discharge to rehabilitation 
or to the community must be planned in advance.
Patient Selection
Depending on the aetiology of chronic respiratory fail-
ure, criteria for patient selection for HMV and the inter-
face used differ.
Obesity Hypoventilation Syndrome
OHS, chronic hypercapnic respiratory failure due to 
obesity with or without associated obstructive sleep ap-
noea syndrome (OSAS), is the most common indication 
for HMV in many countries. Positive pressure ventilation 
is indicated in patients with OHS at the time of diagnosis 
to improve respiratory mechanics, adjust neural respira-
tory drive, and keep the upper airway patent during sleep. 
HMV can usually be applied non-invasively. However, 
HMV is commonly initiated within the course of emer-
gency hospitalisations due to acute on chronic respira-
tory failure in OHS, and patients may be difficult to wean 
from invasive mechanical ventilation. Although both 
CPAP and NIV have been shown to correct respiratory 
failure [9–11], NIV is superior to CPAP in improving ex-
ercise capacity and pulmonary hypertension [12]. The 
degree of sleep hypoventilation and apnoeas or hypop-
noeas contributing to hypercapnia differs across the spec-
trum of OHS/OSAS, and the dominating underlying 
sleep-disordered breathing may guide the choice of initial 
positive pressure ventilation. CPAP is easier to imple-
ment and less expensive, and both CPAP and NIV have 
been shown to improve gas exchange. If NIV is needed to 
effectively control hypoventilation in the initiation phase, 
a down-step to CPAP might be possible after a few weeks 
or months [13]. The indication for HMV as treatment for 
chronic respiratory failure should be re-evaluated after 
substantial weight loss, e.g., in response to bariatric sur-
gery [14–16].
OHS patients often need relatively high expiratory 
positive airway pressure (EPAP, 8–14 cmH2O) to guaran-
tee upper airway patency, and additional pressure sup-
port to correct hypoventilation: the back-up rate can be 
set quite high (14–18/min). Additional supplementary 
oxygen is sometimes needed in the initial phase of venti-
lation, but usually unnecessary with an effective ventila-
tor setting and in the absence of pulmonary comorbidity.
Neuromuscular and Chest Wall Disease
NIV is usually initiated for symptomatic chronic alveo-
lar hypoventilation, but several parameters are monitored 
proactively during regular follow-up to assess progressive 
respiratory muscular weakness and to detect looming 
ventilatory failure in patients with slowly progressive 
NMD/CWD, e.g., forced vital capacity (FVC), maximum 
inspiratory and expiratory pressures, peak cough flow, ar-
terial oxygen saturation, and carbon dioxide partial pres-
sure every 6–12 months in adult patients with muscular 
dystrophy type Duchenne [17, 18]. Since ambulation has 
usually been lost previously in NMD, decline in FVC and 
respiratory failure might occur with very few symptoms 
(e.g., no exercise dyspnoea). FVC is an important predic-
tor of respiratory failure, e.g., FVC < 50% makes ventila-
tory failure likely. In patients with deformities of the ver-
tebral spine and chest wall, the percent predicted of FVC 
should be calculated based on the arm span [19]. Non-
invasive respiratory muscle strength testing (sniff nasal 
inspiratory pressure, maximal inspiratory pressure, and 
maximal expiratory pressure) is also useful in predicting 
respiratory failure [20–22]. Ineffective cough, recurrent 
lower respiratory tract infections, and hypoventilation as-
sociated with right heart failure are the leading causes of 
morbidity and mortality in NMD. An anticipatory moni-
toring approach allows timely initiation of cough assist, 
nocturnal, and subsequent daytime ventilatory support 
[23]. In patients with muscular dystrophy type Duchenne, 
HMV should be discussed and initiated when symptom-
atic nocturnal hypoventilation or advanced respiratory 
muscle weakness develops (FVC or maximal inspiratory 
pressure fall below 50% or 60 cmH2O, respectively) [24]. 
These patients are at risk for daytime ventilatory failure at 
short or intermediate term [25]. NIV usage is usually ex-
tended from night-time into day-time. It can even be ex-
tended to 24-h usage in combination with airway clear-
ance techniques so that tracheostomy can be avoided. Sur-
vival and quality of life benefits due to HMV have been 
demonstrated in several studies in patients with muscular 
dystrophy [26] and CWD [18] and recently also in pa-
tients with motor neurone disease (also non-invasively 
when bulbar function is sufficient) [27–29]. In patients 
with rapidly progressive NMD such as bulbar and respira-
tory forms of amyotrophic lateral sclerosis, for example, 
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assisted ventilation via a mask is generally preferred, and 
tracheostomy is rarely recommended to avoid the devel-
opment of a locked-in state and associated suffering dur-
ing the final stages of life. Although there are very few 
randomised controlled trials, HMV has found a wide-
spread application in patients with NMD/CWD.
Chronic Obstructive Pulmonary Disease
Chronic hypercapnia in patients with COPD is associ-
ated with a particularly bad outcome with a high mortal-
ity and frequent hospitalisations. Patient selection and 
the correct ventilation strategy is crucial in COPD. Evi-
dence for benefit on hospital admission-free survival and 
quality of life in COPD is accumulating since the intro-
duction of high-intensity NIV aiming at normalising 
paCO2 [2, 30, 31]. In addition, EPAP has to be titrated 
high enough to overcome intrinsic positive airway pres-
sure and its inspiratory threshold load, but a too high 
EPAP may aggravate hyperinflation. Patient-ventilator 
asynchronies are common in COPD and should be con-
sidered during set-up. Overall, titrating NIV in COPD 
needs time and monitoring. COPD patients usually need 
a much higher pressure support than NMD or obesity-
related respiratory failure. COPD patients usually also re-
quire additional long-term oxygen to HMV to address 
both the gas exchange problem and ventilatory failure. 
HMV is typically applied non-invasively during sleep and 
extended into the daytime as needed. However, some pa-
tients who cannot be weaned after intubation and me-
chanical ventilation after acute on chronic respiratory 
failure might be ventilated via tracheostomy. Patient se-
lection criteria for HMV in COPD have recently been es-
tablished: clinicians should reassess post-acute NIV 
COPD patients 2–4 weeks after clinical recovery; if the 
paCO2 remains > 7 kPa, NIV should be considered [2]. 
However, NIV should also be discussed in stable patients 
with slowly progressive hypercapnia on optimal medical 
treatment without a history of NIV during an acute exac-
erbation of COPD (chronic vs. acute on chronic hyper-
capnic respiratory failure). The credo is: select the right 
patients and ventilate adequately. However, treating 
COPD patients with long-term NIV needs time, experi-
ence, and a dedicated infrastructure.
Interfaces
Initiation of HMV starts with the choice of the appro-
priate interface. NIV via an oro-nasal or nasal mask has 
several advantages over invasive ventilation. In particu-
lar, mask ventilation allows for convenient, intermittent 
use during sleep or resting periods, or as needed other-
wise. The opportunity to speak and eat/drink during nat-
ural breathing and to be free of any technical support 
during daytime hours and social interactions is very im-
portant to many patients as it allows them to avoid the 
stigma of appearing to be handicapped. Invasive HMV 
via a tracheostoma may be preferable for patients with 
large amounts of secretions that require endotracheal/
bronchial suctioning and for those with a need for con-
tinuous 24-h ventilatory support (see below). However, 
large amounts of secretions may also complicate trache-
ostomy ventilation, especially in patients with bronchi-
ectasis.
Interfaces for NIV
The choice of the right interface is required for suc-
cessful NIV. The mask is a key factor for patient comfort 
and adherence to therapy and therefore long-term suc-
cess of NIV. Oro-nasal (full-face) interfaces are usually 
the first choice when starting NIV because many pa-
tients with decompensated chronic hypercapnic respira-
tory failure tend to breathe through their mouth. It is 
recommended to test several masks for patient comfort 
and effectiveness. Oro-nasal masks, nasal masks, and na-
sal pillows are most often used in long-term HMV 
(Fig.  1). Oro-nasal masks are usually associated with 
lower leakage during sleep. Nasal masks or pillows may 
be better tolerated during daytime, especially in 24-h 
ventilator dependency, as generally patients learn to 
speak and swallow even during application of NIV. 
When choosing interfaces, it is always necessary to check 
the compatibility of the mask with the ventilator circuit, 
e.g., an open single-limb circuit requires leak orifices in 
a vented mask or in the circuit to prevent CO2 rebreath-
ing. The manual skills of the patient should also be ap-
propriately considered in the selection of the mask since 
some models are more challenging to apply or more 
fragile than others (Fig. 1). Regular check and replace-
ment of the interfaces is important during HMV. Avail-
ability of different masks may be useful in case of pres-
sure ulcers and other mask-related side effects. Mask fit-
ting and practice in handling may help to reduce local 
side effects and air leaks. It is necessary to regularly reas-
sess mask fit and air leaks during treatment (straps tend 
to loosen). Nowadays, a less common interface for NIV 
than masks is a mouthpiece (Fig. 1). Mouthpiece ventila-
tion might be used part-time during daytime in the 
wheelchair in patients with NMD if better tolerated and 
considered safe (e.g., good mouth closure and function-
HMV for Chronic Respiratory Failure 5Respiration 2019;98:1–15
DOI: 10.1159/000499316
ing neck movements) [32]. Many ventilators provide a 
specific mode for mouthpiece ventilation. Its advantages 
over NIV by a mask are mainly the opportunity for in-
termittent use as needed by patients who are unable to 
put on a mask themselves. Furthermore, mouthpiece 
ventilation during daytime might facilitate speaking and 
eating [32].
Interfaces for HMV via Tracheostomy
Only a small proportion of patients receives HMV via 
tracheostomy [33]. Patients with spinal cord injuries and 
NMD build the largest groups. An advantage is the pos-
sibility for airway suctioning and the prevention of air 
leakage (when cuff inflated) while still allowing speech 
when the cuff is deflated and a one-way valve (Passy-
Muir or similar valve) set in place. There are different 
cannulas available (e.g., cuffed, uncuffed, rigid, flexible, 
inner/outer tube, speaking valve) (Fig. 2). The choice of 
the right tracheostomy tube length and diameter is im-
portant. A cuffed tube seals the airway; however, it has 
several disadvantages, e.g., renders the patient unaccus-
tomed to swallowing and can cause damage to the tra-
cheal wall (cuff pressure has to be monitored). While 
necessary in the acute phase of a tracheostomy, a con-
tinuously inflated cuff is often not necessary in stable 
long-term HMV. Tracheostomy is associated with spe-
cific possible complications such as life-threatening 
bleeding, ventilator-associated pneumonia, mucus plug-
ging, or tracheal granuloma formation and stenosis.
Selection of the Ventilator Circuit and Settings
When selecting the specific type of ventilator for a par-
ticular patient one should consider the degree of depen-
dency (full ventilatory dependency, intermittent ventila-
tory use, need for battery powered operation), NIV or 
invasive ventilation, the required pressure range, physical 
impairment, comorbidities and mobility of the patient, as 
well as know-how and preferences of the local care team.
For mask HMV in patients requiring only intermittent 
support, a single-limb vented circuit is usually selected. It 
needs exhalation orifices in the mask (Fig. 1), in a connec-
tor between the mask and the tube, or the distal circuit to 
prevent rebreathing [34]. A one-way valve is mounted just 
before or in the mask for safety reasons assuring sponta-
neous breathing in case of ventilatory failure. Rebreathing 
in a vented single limb circuit is affected by the size of the 
orifices and the EPAP. In mask ventilation, tidal volume 
and applied minute ventilation cannot be precisely esti-
mated, and setting alarms on these variables are therefore 
not routinely performed and are not reliable.
a b c
d e f
Fig. 1. Examples of masks for NIV: oro-na-
sal (a, d) and nasal masks (b, c), and de-
tailed view of leak orifices and safety valve 
of an oro-nasal mask (e) and an angled 
mouthpiece (f).
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A single-limb non-vented circuit has an exhalation 
valve controlled by the ventilator at the distal end of the 
circuit [35]. A double-limb circuit consists of an inspira-
tory and expiratory limb (Fig. 3). These are connected to 
the ventilator via non-rebreathing valves, and to the in-
terface via a Y-piece. Non-vented circuits with valves are 
commonly used for invasive ventilation. A double-limb 
system allows for precise estimation of administered and 
exhaled tidal volume and minute ventilation and for the 
detection of unintended leaks. In addition, various alarms 
can be set for life-supporting ventilation.
Ventilator Mode and Settings
Table 1 summarises the main modes and settings used 
during HMV. The selection is guided by the underlying 
disease and dependency, but individual adjustments are 
required for optimal efficacy and comfort.
Bi-Level Pressure Support Ventilation
Bi-level pressure support ventilation (BiPAP, PSV) – 
most often spontaneous-timed (ST) mode with a mini-
mal back-up rate – is the most frequently used mode in 
HMV according to a European survey [36]. Individually 
different levels of pressure support (inspiratory positive 
airway pressure [IPAP] minus EPAP) will be necessary to 
correct alveolar hypoventilation. Tidal volume increases 
nearly linearly with increasing pressure support. Pressure 
support is commonly limited by leak and patient discom-
fort above 25–30 cmH2O in case of NIV. Based on the 
mode, ventilation will be controlled (timed mode, T), as-
sisted (spontaneous mode, S) or both (ST). In pressure 
support ventilation, optimal EPAP, trigger sensitivity, 
pressurisation (rise time of pressure support), IPAP or 
level of pressure support, and cycle-off (expiratory trigger 
sensitivity) have to be titrated. EPAP is titrated to keep the 
upper airway open and/or to overcome intrinsic positive 
end-expiratory airway pressure (PEEP) to improve pul-
monary mechanics and reduce the work of breathing de-
pending on the underlying pathophysiology of ventila-
a
b
d
c
e
f
Fig. 2. Tracheal cannulae. a Three types of rigid inner cannulae 
fenestrated and non-fenestrated. b Speaking valve and cover piec-
es for room air breathing and oxygen administration. c Fenestrat-
ed, cuffed tracheal cannula, with fixation band (d). e Flexible, un-
cuffed cannula, with its inner tube (f).
Fig. 3. Ventilator circuits. Upper part: single-limb circuit with ex-
halation valve; lower part: double-limb circuit.
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tory failure. EPAP also improves functional residual ca-
pacity and ventilation-perfusion matching. Ventilation 
should aim at normalising or reducing paCO2 and at a 
tidal volume of 7–9 mL/kg ideal body weight [30]. How-
ever, tidal volume is often under- or overestimated by 
ventilator software, especially in the presence of uninten-
tional leaks. Trigger sensitivity (flow-dependent > pres-
sure-dependent > complex algorithms) should be chosen 
to avoid excessive work of breathing, wasted efforts, and 
auto-triggering/cycling. A shorter rise time is needed in 
obstructive airway disease compared to restrictive airway 
disease for a suitable inspiration to expiration ratio, but 
has also to be titrated according to patient comfort. Cycle-
off criteria should be chosen to match the duration of in-
spiration with the neural inspiratory time and should also 
consider patient comfort. Cycling-off at a higher percent-
age of peak inspiratory flow (percentage of peak inspira-
tory flow is a commonly used cycling-off criterion) is cho-
sen in COPD compared to NMD/CWD. The presence of 
air leaks may interfere with flow-cycling. Most ventilators 
allow setting a minimal and maximal inspiration time to 
set a safety limit for the cycling window.
Pressure-Controlled Non-Invasive Ventilation
Pressure-controlled non-invasive ventilation is the 
second most often used mode and has a fixed inspiratory 
time (whereas there is a cycle-off criterion and a maxi-
mum inspiratory time in bi-level pressure support venti-
lation).
Volume-Targeted Modes
Volume-targeted modes have recently been used. A 
hybrid mode providing an assured tidal volume during 
pressure support ventilation has become available (e.g., 
VAPS/volume-assured pressure support or AVAPS/av-
erage volume-assured pressure support). IPAP is adapted 
within pressure support or pressure-controlled modes to 
guarantee a pre-set averaged tidal volume (usually around 
6–8 mL/kg of ideal body weight). However, there is cur-
rently no evidence for a superiority of (A)VAPS over bi-
level pressure support ventilation in specific settings. In 
addition, these modes have certain pitfalls such as a loss 
of pressure support in case of a higher than targeted tidal 
volume, or the fall or increase of pressure support in the 
presence of unintentional leaks depending on the circuit.
Volume-Controlled Ventilation and Intermittent 
Positive Pressure Ventilation
Volume-controlled ventilation and intermittent posi-
tive pressure ventilation are seldom used in HMV. Vol-
ume-controlled ventilation may have more gastrointesti-
nal side effects due to the changes in IPAP.
Table 1. Ventilator modes and settings commonly used in HMV
Abbreviation Mode Settings*
CPAP Continuous positive airway pressure CPAP, maintained through all phases of the breathing cycle
PSV-S Pressure support ventilation,
spontaneous mode
IPAP, EPAP, TImin, TImax, inspiratory and expiratory (cycle) trigger 
sensitivity, inspiratory rise time
PSV-ST Pressure support ventilation,
spontaneous/timed mode
IPAP, EPAP, respiratory frequency, TImin, TImax, inspiratory and 
expiratory (cycle) trigger sensitivity, inspiratory rise time, expiratory 
pressure decrease speed (cycle-off)
PSV-T Pressure support ventilation, timed 
mode
IPAP, EPAP, respiratory frequency, TI, inspiratory rise time, 
 expiratory pressure decrease speed, cycle-off
(a)PCV (assisted) Pressure control ventilation IPAP, EPAP, respiratory frequency, TI (TI:TE), inspiratory trigger 
sensitivity, inspiratory rise time, expiratory pressure decrease speed
VAPS/AVAPS
and tri-level 
PAP
(average) Volume-assured pressure
support ventilation and variable
inspiratory/expiratory positive pressure 
ventilation
EPAP fixed or variable (autoEPAP), variable pressure support with PS 
min, PS max, target volume, TImin, TImax, inspiratory and 
 expiratory (cycle) trigger sensitivity, inspiratory rise time, expiratory 
pressure decrease speed, cycle-off* Any particular setting may not be available in all ventilators, depending on brand. IPAP, inspiratory positive airway pressure; EPAP, 
expiratory positive airway pressure; TImin, minimal inspiratory time; TImax, maximal inspiratory time; TI, inspiratory time; TE, 
expiratory time.
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Tri-Level NIV
Tri-level NIV is a term used for a combined bi-level 
positive pressure ventilation mode that provides fixed or 
variable inspiratory pressure support according to the 
modes described above and applies a variable, auto-ad-
justed EPAP similar to autoCPAP used to treat OSA. This 
combined mode may be advantageous in selected pa-
tients with OHS/OSA or other forms of combined hy-
poventilation and obstructive or central sleep apnoea, but 
no scientific evidence is available to date to demonstrate 
its superiority over standard NIV modes [37].
Humidification and Additional Support
Not every patient on NIV requires additional humidi-
fication since breathing through the nose assures warm-
ing and humidification of the inspired air like during nat-
ural breathing. Dryness of the nose and mouth and exces-
sive nasal secretion may reflect oral leaks during nasal 
ventilation or mouth breathing. In these cases, the use of 
an oro-nasal (full-face) mask is advisable. Alternatively, 
or in addition, a passive humidifier may provide addi-
tional comfort. In invasive HMV via a tracheostomy tube, 
heated humidification is advisable to prevent drying out 
of the central airways which can result in dangerous air-
way obstruction through tedious secretions and mucus 
plugs. Some patients on HMV via tracheostomy use hu-
midification only when stationary but have a wheel-chair 
mounted ventilator without humidifier to prevent mo-
tion-induced water accumulation in the circuit when 
driving around.
Patients with underlying diseases with impaired gas 
exchange may need the addition of long-term oxygen 
therapy to HMV. Most ventilators for HMV have a dedi-
cated, low-pressure oxygen inlet. It shuts off automati-
cally in case of interruption of ventilation in order to 
avoid fire hazard from high oxygen concentrations accu-
mulating within the ventilator. High-pressure/flow oxy-
gen supplementation is not generally available in the 
home care setting.
Besides treating chronic respiratory failure, the respi-
ratory physician caring for patients on HMV should also 
be aware of, monitor, and treat comorbidities and other 
manifestations of specific diseases (e.g., in NMD) unre-
lated to or interfering with effective NIV.
Mobilisation of secretion should be assisted by cough-
ing techniques, postural drainage, physiotherapy, and in 
advanced respiratory muscle weakness with ineffective 
cough, by an exsufflation-insufflation device (cough as-
sist). A cough assist, providing mechanical insufflation-
exsufflation to support airway clearance, is commonly 
prescribed to prevent atelectasis and pneumonia in pa-
tients with NMD when peak cough flow is lower than 
< 270 L/min (4.5 L/s) [23, 38–40]. The peak cough flow 
thresholds of 270 L/min and 160 L/min have been shown 
to predict inability to cough to effectively clear airway se-
cretions and chronic respiratory failure, respectively [38, 
41]. An experienced physiotherapist is needed to instruct 
and assist the patient in the use of a cough assist.
A percutaneous endoscopy gastrostomy is indicated in 
patients with impaired swallowing to avoid respiratory 
complications and to allow for sufficient administration 
of fluid and nutrition without stressing the patient. In pa-
tients on HMV, it has been shown to be beneficial to place 
a percutaneous endoscopy gastrostomy with a gastric and 
intestinal tube. The gastric tube allows deflation in case of 
aerophagia, which is a common side effect of positive 
pressure ventilation.
Especially in NMD and in paraplegic patients, admin-
istration of sufficient fluids, properistaltic agents, and lax-
ative drugs are essential to avoid constipation and more 
severe abdominal complications as consequences of the 
disturbed gastrointestinal motions [42].
Monitoring
Monitoring of NIV focuses on improving patient-ven-
tilator synchrony and reducing leakage, besides maximis-
ing effectiveness in terms of correcting respiratory failure 
and sleep-disordered breathing. Optimising settings by 
monitoring physiological parameters will improve patient 
comfort and adherence to long-term NIV. Monitoring op-
tions are clinical and haemodynamic parameters, arterial 
blood gas analysis, pulse oximetry, transcutaneous pCO2, 
respiratory polygraphy (with the possibility of comparing 
respiratory effort and ventilator-provided support), and 
ventilator-dependent information on timing, triggering, 
pressure, flow, and volume. The choice of monitoring fa-
cilities depends on the setting and complexity of the pa-
tient’s condition; however, a minimum of monitoring to 
guarantee effectiveness and tolerability is always necessary.
Arterial Blood Gas Analysis
Arterial blood gas is a very common tool used to assess 
both ventilation and oxygenation as well as gas exchange 
by measurement of the pH and arterial partial pressure of 
CO2 and O2 (paCO2, paO2) and calculated parameters 
(e.g., alveolo-arterial pO2 gradient, base excess). Its re-
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sults are rapidly available and allow prompt decision 
making and adaptation of ventilator parameters. It is the 
gold standard to assess ventilation.
Transcutaneous Capnometry
Transcutaneous monitoring of carbon dioxide (ptc-
CO2) is a valid method to non-invasively and continu-
ously monitor changes of ptcCO2 during NIV [43]. The 
level of agreement with paCO2 is acceptable and the great 
advantage is the possibility to monitor trends over time 
non-invasively [44].
Polysomnography and Respiratory Polygraphy
A more pragmatic approach than polysomnography 
is respiratory polygraphy combined with transcutane-
ous pCO2 measurement (Fig.  4). Monitoring of chest 
Sum
Thorax
Abdomen
Heart R
P mask
SpO2
ptcCO2
Sum
Thorax
Abdomen
Heart R
P mask
SpO2
ptcCO2
Fig. 4. Polygraphic recordings during initial adaptation of mask 
ventilation in a patient with chronic hypercapnic respiratory fail-
ure due to chronic obstructive pulmonary disease. The time series 
show 60-s periods of chest wall excursions by inductive plethys-
mography, pulse oximetry (SpO2), pulse rate, mask pressure, and 
transcutaneous capnography (ptcCO2). In the upper panel, there is 
near perfect synchronisation of the chest wall motion with the ven-
tilator. In the lower panel, there is patient/ventilator asynchrony 
with irregular breathing, paradoxical chest wall excursions (double 
arrows), trigger failure (arrows with broken lines), and inadequate 
triggering (arrows with solid lines). Patient-ventilator asynchrony 
results in inefficient ventilation with an increase in ptcCO2 and a 
drop in SpO2. Heart R, heart rate; P mask, mask pressure.
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wall motion by respiratory inductance plethysmogra-
phy together with ventilator-derived pressure and flow 
as well as pulse oximetry and capnometry allows titra-
tion and optimisation of HMV based on physiologic 
monitoring. Advanced physiologic monitoring such as 
electromyography of respiratory muscles or oesopha-
geal pressure has provided physiological insights but 
has not been implicated in routine clinical practice so 
far.
Ventilator Curves
Several ventilators allow real-time graphical visualisa-
tion of variables (Fig. 5) such as volume, pressure, and 
flow over time (time series curves) or the interaction be-
tween two variables over the course of a breath (loop). 
This can provide information on whether breaths are 
spontaneously triggered (started) and cycled (stopped) or 
mandatory (when they are triggered or cycled or both by 
the ventilator).
Ventilator Software Data Chip
Downloading and checking ventilator software sta-
tistics that usually provide information on setting, us-
age, tidal volume, minute ventilation, pressures, spon-
taneous and machine triggered breaths, and leakage is 
especially helpful to adjust settings and encourage the 
patient during follow-up of HMV (Fig. 6). Large unin-
tentional leaks my lead to side effects such as sleep 
fragmentation and patient-ventilator asynchrony, and 
to insufficient ventilation although pressure support 
ventilation may compensate for unintentional leaks 
[45, 46]. Thresholds for high measured leaks depend on 
the ventilator and the interface and have not been es-
tablished by convincing evidence. Moreover, rapid 
changes in leaks seem to be more relevant than abso-
lute values of leak flow in terms of patient disturbance. 
In any case of an excessive and highly variable leak, 
interface fitting and handling by the patient must to be 
evaluated. Chin straps might be helpful with a nasal 
interface [47]. Humidification may reduce nasal resis-
tance [48].
Telemedicine
The role of telemedicine in improving adherence 
and settings, and thereby patient outcomes, is not yet 
clear [49, 50]. Although most current ventilators used 
for HMV can be interfaced with pulse oximetry to 
monitor oxygenation, transcutaneous self-monitoring 
of carbon dioxide in the patient’s home is not practi-
cally feasible due to the technically challenging applica-
tion and high cost of the capnography device sensor. 
This imposes an important limitation to telemonitoring 
of patients on HMV. In theory, telemonitoring offers a 
potential for better use of resources and faster interven-
tion in case of insufficient usage, clinical deterioration, 
or sub-optimal ventilator setting, and awareness of this 
option will increase. Different monitoring parameters 
like applied pressure, breathing pattern, estimated ven-
tilation, pulse oximetry, and built-in software informa-
tion are available via telemonitoring. However, stan-
dards on how to use telemonitoring as part of an HMV 
service and clear evidence on its benefit are not yet 
available. Figure 7 shows a suggested simplified algo-
rithm for monitoring levels of HMV during sleep and 
wakefulness.
HMV Service and Follow-Up
It has to be highlighted that the right setting is impor-
tant for successful HMV. The facilities and opportunities 
may vary among health care systems and countries. 
HMV is most successful if performed comprehensively 
in a collaborative team comprising the patient and his/
her family, home care personnel (either from the com-
munity, a non-profit organisation such as the Lung 
Ligue, or a commercial company), a family physician, 
and professionals from various services including respi-
ratory medicine, cardiology, gastroenterology, nutri-
tional support, neurology, and others depending on spe-
cific problems. A regular exchange of essential informa-
tion between the patient and the different care givers is 
important. Adequate facilities with experience in the im-
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Fig. 5. Ventilator display showing pressure and volume curves in 
real-time along with numerical information on timing, applied 
volume, and pressure.
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Fig. 6. Graphical display of data downloaded from the ventilator 
during HMV in a patient with chronic obstructive pulmonary dis-
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mode over the course of 4 months. The lower panels show detailed 
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helps to verify optimal efficacy and use during long-term HMV.
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plementation of HMV and long-term support are man-
datory. A dedicated setting should include an outpatient 
and inpatient clinic, a sleep laboratory, and a high-de-
pendency unit with specialised medical and paramedical 
personnel and equipment. Access to an emergency room 
and intensive care unit should be readily available. Regu-
lar follow-up of patients treated with HMV is essential to 
ensure that HMV is effective, the patient is using it ap-
propriately, and the equipment is functional [51]. In gen-
eral, an outpatient follow-up in an NIV service is re-
quired at least yearly; however, depending on the course 
of the disease and episodes of acute on chronic respira-
tory failure, a closer follow-up is needed, especially in the 
initiation phase.
Disease- and Ventilator-Specific Problems
The forms and modes of ventilation as well as the un-
derlying disease causing chronic respiratory failure har-
bour specific risks associated with HMV. Some examples 
are given.
Invasive ventilation via tracheostomy may result in 
bleeding from the tracheostomy side, cuff-induced tra-
cheal ulcers or stenosis, speech problems, airway obstruc-
tion by secretion, and ventilator-associated pneumonia, 
whereas NIV involves the risk of local interface side ef-
fects (such as ulcers) and leakage.
Intercurrent lower respiratory tract infections with ag-
gravated airway secretions can result in acute on chronic 
ventilatory failure on HMV and make intubation neces-
sary. Intercurrent respiratory tract infections and reduc-
tion of fluid and food intake make the patient prone to 
life-threatening metabolic derangements [52]. Specialist 
chest physiotherapy and cough assist might be used to 
prevent mucus plugging and atelectasis.
Bulbar dysfunction in NMD increases the risk of aspi-
ration, which can be assessed by a swallowing test. Gas-
trostomy can be used as an alternative feeding method; 
however, there is still the risk of aspiration of oral secre-
tions.
COPD predisposes to patient-ventilator asynchrony. 
Therefore, monitoring of respiratory effort and patient-
ventilator synchrony during initiation and titration of 
NIV is of great importance in these patients.
Future Developments and Outlook
There are continuously ongoing developments in pa-
tient interfaces that will enhance the comfort and effec-
tiveness of NIV. Novel ventilator modes that automati-
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cally adjust settings (“smart” ventilators) to assure a tar-
get minute volume or a minimum tidal volume and that 
adjust to physiologic changes during changes in sleep 
stages and positions are likely to be used more. However, 
benefits and harms of these novel modes have to be sci-
entifically evaluated first, and it will always remain im-
portant that an experienced person is setting the ventila-
tor up. In addition, high flow devices might be used in 
specific subgroups, although the implementation of this 
outside the hospital (home high flow) might be difficult 
to realise, and the place for high flow therapy is more like-
ly in acute than in chronic respiratory failure. Telemedi-
cine is increasingly available, but standards for data han-
dling are not defined. Before its implementation in NIV 
services, it needs to be demonstrated that telemedicine 
improves patient outcomes or reduces hospitalisations 
[49].
In summary, HMV has the potential to improve vari-
ous clinical and physiological outcomes. It may reduce 
work of breathing and metabolic demand, increase tidal 
volume, and reduce paCO2. This may reset the deranged 
chemoreceptors, as well as improve respiratory mechan-
ics, prevent atelectasis, and improve ventilation/perfu-
sion matching. Monitoring is needed to improve and re-
assure these outcomes and to avoid adverse effects, unin-
tentional leaks, and patient-ventilator asynchrony. 
Regular assessment of the effectiveness of HMV is recom-
mended during follow-up, depending on the course of the 
underlying cause of chronic respiratory failure, usually by 
daytime arterial blood gas analysis and nocturnal capnog-
raphy and pulse oximetry.
Conclusions
The key concepts to successful HMV are an experi-
enced team selecting the right patients, initiating NIV 
timely, and following up patients with chronic respira-
tory failure regularly in a dedicated interdisciplinary ser-
vice. Possible extra-pulmonary manifestations of the un-
derlying disease and comorbidities should always be kept 
in mind. Optimal access to HMV and follow-up in spe-
cialised centres for HMV for the large group of patients 
with an indication of and benefit from HMV are essential.
The frontiers remain the implementation of the cur-
rent knowledge in clinical practice and providing HMV 
according to current standards to all those in need.
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